Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK discusses the results of APROMISS: a Phase III trial investigating the safety and efficacy of hydrochloride monotherapy with the multi-tyrosine-kinase inhibitor anlotinib versus dacarbazine in previously treated patients with metastatic or advanced synovial sarcoma (NCT04044768). The primary endpoint of median progression free survival (mPFS) was met; mPFS was 2.89 months in the anlotinib group versus 1.64 months in the dacarbazine group with a hazard ratio (HR) of 0.444. Moreover, the progression free rate at 12 months was 27% versus 4%, in the treatment and control groups respectively, and there were no unexpected safety signals. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
